Company

Vero Biotech, Inc.

Vero Biotech develops inhaled nitric oxide delivery systems for cardiopulmonary conditions.

About

Vero Biotech develops inhaled nitric oxide delivery systems, including GENOSYL® for persistent pulmonary hypertension in newborns. Founded in 2006 in Georgia, US, the company raised USD 65 million in venture debt from Horizon Technology Finance in February 2024.

2Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in